

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: AFisher@unither.com

**ISRAELI MINISTRY OF HEALTH APPROVES REMODULIN TO TREAT
PULMONARY ARTERIAL HYPERTENSION**

RESEARCH TRIANGLE PARK, N.C., and SILVER SPRING, Md., Nov. 4 -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the Drug Registration Department of the Israeli Ministry of Health has approved Remodulin(R) (treprostinil sodium) Injection for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. No further clinical studies are required. Approximately 25 patients are currently being treated with Remodulin in Israel.

The Israeli approval represents the second international approval of Remodulin following United States Food and Drug Administration approval on May 21, 2002 and the Canadian Therapeutic Products Directorate approval on October 4, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France.

United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.